Federico Caligaris-Cappio, MD of Università Vita-Salute San Raffaele, Milan, Italy, talks about the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), which will hold a meeting in New York in 2017 (http://www.iwcll2017.org/). Prof. Caligaris-Cappio explains that the iwCLL has an interesting composition with scientists, translational scientists and clinicians attending. The iwCLL, as every other scientific community or group, is caught between two aspects. One aspect is what we would like to know, the other is what we need to apply to patients. Therefore, the iwCLL is trying to bridge these two aspects and is trying to put forward as much science as possible and to translate into clinical practice as much science as possible. He explains that once new drugs are used or new trials are made, there is always unexpected data. It is very important to understand why these results are unexpected and if we are able to do this, it will be very likely to produce important advantages for the patients. He explains that iwCLL was created in the early 80s as a platform for people who were interested in this malignancy, which was not considered interesting at that time. Prof. Caligaris-Cappio joined the iwCLL where they started working together and arranging meetings to push forward both the science and clinical trials in CLL. After many years, some results have been achieved and major advances made as CLL has become one of the most important studied diseases. He explains that not all CLL patients are currently able to be cured but research is very close to understanding how to cure most patients.
Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.